Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics IncfiledCriticalAmicus Therapeutics Inc
Publication of AR124827A1publicationCriticalpatent/AR124827A1/es
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente divulgación se refiere al suministro por virus adeno-asociado recombinante (rAAV) de un polinucleótido de lipofuscinosis neuronal ceroidea 3 (CLN3). La divulgación provee rAAV y métodos para usar el rAAV para la terapia génica de CLN3 de la lipofuscinosis neuronal ceroidea o la enfermedad de CLN3-Batten.
ARP220100241A2021-02-052022-02-07Suministro por virus adeno-asociado de polinucleótido cln3
AR124827A1
(es)
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
Electroacupuncture alleviates nerve injury after cerebra ischemia in rats through inhibiting cell apoptosis and changing the balance of MMP-9/TIMP-1 expression